Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: <i>post hoc</i> analysis of COSMOS
Guselkumab treatment provided substantial benefits across multiple disease domains, with increasing proportions of patients achieving LDA/remission over 1 year, highlighting the effectiveness of guselkumab despite previous inadequate response to TNFi.
Authors
- Carlo Selmi (ORCID: https://orcid.org/0000-0002-0323-0376)
- Clementina López‐Medina (ORCID: https://orcid.org/0000-0002-2309-5837)
- F. Lavie (ORCID: https://orcid.org/0000-0002-5213-257X)
- Daniel Aletaha (ORCID: https://orcid.org/0000-0003-2108-0030)
- Xenofon Baraliakos (ORCID: https://orcid.org/0000-0002-9475-9362)
- Emmanouil Rampakakis (ORCID: https://orcid.org/0000-0002-7427-8246)
- Laura C. Coates (ORCID: https://orcid.org/0000-0002-4756-663X)
- Laure Gossec (ORCID: https://orcid.org/0000-0002-4528-310X)
- Mohamed Sharaf (ORCID: https://orcid.org/0009-0003-9847-2996)
Institutions
- Humanitas University (IT)
- Janssen (Belgium) (BE)
- Inserm (FR)
- McGill University Health Centre (CA)
- Nuffield Orthopaedic Centre (GB)
- Sorbonne Université (FR)
- University of Oxford (GB)
- Janssen (France) (FR)
- Rheumazentrum Ruhrgebiet (DE)
- Johnson & Johnson (France) (FR)
- Instituto Maimónides de Investigación Biomédica de Córdoba (ES)
- Johnson & Johnson (Sweden) (SE)
- JSS Medical Research (India) (IN)
- Pitié-Salpêtrière Hospital (FR)
- Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR)
- Johnson & Johnson (Israel) (IL)
- IRCCS Humanitas Research Hospital (IT)
- McGill University (CA)
- Cordoba University (US)
- Medical University of Vienna (AT)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-10-22
- DOI
- https://doi.org/10.1093/rheumatology/keae586
- Citations
- 1
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.45
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- Biogen
- Celgene
- Celltrion
- Swedish Orphan Biovitrum
- Medac
- Samsung
- Janssen Biotech